Nanostrategies to Develop Current Antiviral Vaccines

Rodrigues, Gisele Regina; Sousa, Maurício Gonçalves da Costa; Silva, Dieime Custódia da; Rezende, Taia Maria Berto; Morais, P.C.; Franco, Octávio L.

doi:10.1021/acsabm.0c01284

Cited by 3 publications

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compound should maintain stability against proteases and nucleases, resist in acid and basic environments, and permeate through tissues to reach the target site, avoiding nonspecific delivery . Moreover, the absorption of bioactive compounds needs to trigger cellular internalization pathways either by adhesion onto the cell membrane or by specific interactions of the ligand–receptor type to increase therapy efficacy. , In such a manner, the design and control of biomaterials in the nanoscale can impact the development of materials that gather different skills to overcome these extra- and intracellular barriers. These concepts are essential in vaccine development.…”

Section: Introductionmentioning

confidence: 99%

Layer-by-Layer Assembly of Polymeric Nanoparticles with Heparin-RBD Complexes as an Adjuvant for SARS-CoV-2 Protein-Based Vaccines

Delechiave,

de Oliveira Silva,

de Castro-Amarante

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Multilayered polymeric particles work as carriers of compounds with controlled release triggered by the layer's disassembly, allowing chemical stability along with transport through the bloodstream and tissues. Here, we present versatile multilayered polymeric particles as a vaccine approach against COVID-19 based on coupling a recombinant form of the receptor binding domain (RBD) antigen of the SARS-CoV-2 Spike proteins. The particle core comprises poly(D,L-lactide) coated with Triton X-100 and polyethylenimine, prepared by nanoemulsion/solvent evaporation method and functionalized with heparin by layer-bylayer (PLTP-H). The recombinant RBD is anchored to the nanoparticles by the negative outer layer (PLTP-H-RBD). The nanoparticles reached a complexation efficiency of 95% for the RBD and a final hydrodynamic diameter of 140 nm with a zeta potential of −46 mV. No toxicity was recorded with the nanoparticles using cultured mammalian cells or after inoculation into mice. The immunization of mice with antigen-loaded nanoparticles induced strong adjuvant effects on the serum levels of RBD-specific IgG antibodies, which were capable of neutralizing the virus under in vitro conditions. Furthermore, PLTP-H-RBD conferred enhanced protective immunity to mice challenged with the SARS-CoV-2 virus. These findings represent a proof of concept for the use of PLTP-H as a delivery and adjuvant strategy for recombinant vaccine antigens aiming at the induction of neutralizing antibodies.

show abstract

Section: Introductionmentioning

confidence: 99%

Layer-by-Layer Assembly of Polymeric Nanoparticles with Heparin-RBD Complexes as an Adjuvant for SARS-CoV-2 Protein-Based Vaccines

Delechiave,

de Oliveira Silva,

de Castro-Amarante

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection

Xu¹,

Yuan²,

Wang³

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects

Nadaf,

Kumbhar,

Bhagwat

et al. 2024

Smart Nanomaterials for Infectious Diseases

View full text Add to dashboard Cite

Increased respiratory tract infections have placed a socioeconomic load on the global healthcare system, particularly in developing nations. The lack of alternative therapeutic options has seriously threatened the health of many populations. With the use of passive, active, or physicochemical targeting techniques, nanomedicine-based delivery systems have been developed to enhance the biopharmacokinetic properties and therapeutic results of drugs effective against lung infections. Owing to their physicochemical properties, controlled in vivo behaviour, and the ability for multimodal imaging, NPs are the preferred contrast agents. This chapter provides an overview of respiratory infections and illuminates several barriers of bacterial infections. The features and benefits of nanosized materials for diagnosing various lung diseases are analysed. The current trends of different nanosystems such as lipid-based vesicles, including solid lipid NPs, nanostructured lipid carriers, polymeric micelles, dendrimers, etc., for treating several life-threatening lung infections, including COVID-19, are reviewed and discussed, highlighting their benefits and limitations. The current state of nanovaccines for treating lung infections is highlighted in a separate section. The challenges and prospects of nanostrategies for treating lung infections are considered in the last section.

show abstract

Nanostrategies to Develop Current Antiviral Vaccines

Cited by 3 publications

References 115 publications

Layer-by-Layer Assembly of Polymeric Nanoparticles with Heparin-RBD Complexes as an Adjuvant for SARS-CoV-2 Protein-Based Vaccines

Layer-by-Layer Assembly of Polymeric Nanoparticles with Heparin-RBD Complexes as an Adjuvant for SARS-CoV-2 Protein-Based Vaccines

Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection

Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects

Contact Info

Product

Resources

About